Agreements reached under this partnership
Business Alliances- 1
Abhishek Maiti, MD, of the Department of Leukemia at MD Anderson Cancer Center, will lead the trial as Principal Investigator.
- 2
The Company will supply the monzosertib required for the trial.
- 3
The Company will bear the trial-related costs under the agreement.
- 4
The trial will be conducted as a Phase 1b study in patients with relapsed/refractory AML to evaluate the safety, tolerability and efficacy of monzosertib monotherapy and triple-combination therapy with AZA/VEN.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This matter will have no impact on the consolidated earnings forecast for the fiscal year ending December 2026.
| Item | Details |
|---|---|
| Name of alliance partner | The University of Texas MD Anderson Cancer Center (テキサス大学MDアンダーソンがんセンター) |
| Alliance partner's business activities | One of the world's leading cancer research and treatment institutions. It also leads the development of numerous innovative treatments in the AML field. |
| Alliance partner's location | Texas, USA |
| Type of alliance | Business Alliances |
| Details of the alliance | Abhishek Maiti, MD, of the Department of Leukemia at MD Anderson Cancer Center, will lead the trial as Principal Investigator., The Company will supply the monzosertib required for the trial., The Company will bear the trial-related costs under the agreement., The trial will be conducted as a Phase 1b study in patients with relapsed/refractory AML to evaluate the safety, tolerability and efficacy of monzosertib monotherapy and triple-combination therapy with AZA/VEN. |
| Contract Date | 5 October 2026 |
| Alliance start date | Preparations for patient enrollment are expected to proceed. |
| Impact on Business Performance | This matter will have no impact on the consolidated earnings forecast for the fiscal year ending December 2026. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The parties agreed on the terms of the clinical trial. The aim is to obtain insights into the clinical utility of monzosertib through the trial and accumulate data to support future development strategies.